Saint-Herblain

Valneva to Host Investor Day in New York City

Retrieved on: 
Tuesday, November 29, 2022
Euronext Paris, VLA, Saint-Herblain, Chikungunya, Q&A, Infection, Valneva SE, Vaccine, BLA, Lyme disease, Pfizer

The event will also be webcast live and archived on the Companys website.

Key Points: 
  • The event will also be webcast live and archived on the Companys website.
  • Valneva will also provide an update on its existing commercial business and select pre-clinical development programs, followed by a financial overview.
  • A live Q&A session will follow the formal presentations with opportunity for virtual attendees to participate in the Q&A.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Appoints Dipal Patel as Chief Commercial Officer

Retrieved on: 
Thursday, November 17, 2022
Growth, CCO, Euronext Paris, VLA, Saskatchewan River Sturgeon Management Board, Saint-Herblain, Knowledge, Chikungunya, Travel, Lyme disease, DIPAL Party, Infection, Vaccine, Pharmaceutical industry

Saint-Herblain (France), November 17, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dipal Patel as Chief Commercial Officer (CCO) and Management Board member.

Key Points: 
  • Saint-Herblain (France), November 17, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dipal Patel as Chief Commercial Officer (CCO) and Management Board member.
  • Ms. Patel is an established commercial leader with over 23 years of experience in the pharmaceutical sector covering commercial strategy, execution, market access and lifecycle management.
  • Thomas Lingelbach, Chief Executive Officer of Valneva, said, Dipals addition to our team represents an important and timely step forward in strengthening Valnevas commercial and strategic leadership.
  • Ms. Patel, newly appointed Chief Commercial Officer of Valneva, stated, The last few years have put an increasing focus on the importance of vaccine preventable diseases.

Valneva Provides Further Update on its COVID-19 Activities

Retrieved on: 
Monday, September 26, 2022
Lyme disease, COVID-19, 1018, World, Severe acute respiratory syndrome coronavirus 2, World Health Organization, Vaccination, Company, VLA, Vero, EU, Technology, Vaccine, Nasdaq, Chikungunya, WHO, VLA2001, Marketing, CpG, Saint-Herblain, Euronext Paris, EMA, Infection, Pharmaceutical industry, Kingdom

Saint-Herblain (France), September 26, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities.

Key Points: 
  • Saint-Herblain (France), September 26, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced a further update on its COVID-19 vaccine activities.
  • The Company is in active discussions with a prospective partner for potentially funding the development of a second-generation COVID-19 vaccine.
  • Valneva currently has agreements to supply VLA2001 to certain EU Member States2 and the Kingdom of Bahrain6.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration

Retrieved on: 
Friday, September 16, 2022
Lyme disease, COVID-19, 1018, World, Severe acute respiratory syndrome coronavirus 2, World Health Organization, Vaccination, European Commission, Company, IDT Corporation, VLA, Vero, EU, History, Biosafety level, Technology, Vaccine, Nasdaq, IDT, Chikungunya, WHO, VLA2001, Marketing, CpG, Saint-Herblain, Euronext Paris, EMA, Infection, Kingdom

As per the commercial manufacturing services agreement signed in November 20211, IDT Biologika produced VLA2001 bulk vaccine at its Biosafety Level 3 facilities in Germany, and Valneva bought the batches that were manufactured so far by IDT.

Key Points: 
  • As per the commercial manufacturing services agreement signed in November 20211, IDT Biologika produced VLA2001 bulk vaccine at its Biosafety Level 3 facilities in Germany, and Valneva bought the batches that were manufactured so far by IDT.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.
  • IDT Biologika is an innovative biotech company with a successful history dating back 100 years.
  • In the US, the IDT Corporation has a manufacturing site for clinical test samples in Rockville, Maryland.

Thanks to a new social impact investment, REALITES is now offsetting its entire carbon footprint

Retrieved on: 
Wednesday, September 7, 2022
Carbon, Solar energy, Partnership, CEO, Forest, Technology, Air pollution, City, Rocket stove, Burn, Compagnie Française d'Assurance pour le Commerce Extérieur, Gold standard, London and Paris Conferences, Energy Manufacturing Co. Inc, Cooking, PEA, Glossary of project management, CO2, Saint-Herblain, Project management, Housing, Group, Economic development, Wood, Woman, United States withdrawal from the Paris Agreement, Health, Environment, Regulatory News Service, Tourism, Renewable energy, Fossil fuel, Natural gas

Thanks to a new social impact investment, REALITES is now offsetting its entire carbon footprint

Key Points: 
  • Thanks to a new social impact investment, REALITES is now offsetting its entire carbon footprint
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Thanks to a new social impact investment, REALITES is now offsetting its entire carbon footprint
    Saint-Herblain, 6 September 2022, 5:45 pm.
  • Thanks to this partnership, REALITES will pre-finance the production of 165,000 improved cookstoves for a total of 4.5 million.
  • This new investment generates enough carbon credits to cover all of REALITES' offsetting needs for the next 5 years.

Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases

Retrieved on: 
Tuesday, September 6, 2022
COVID-19, EMA, Public health, EU, Technology, Safety, Vaccination, WHO, Vaccine, World, VLA, Infection, The Lancet, Lyme disease, Euronext Paris, Lancet, Journal, Severe acute respiratory syndrome coronavirus 2, CpG, Nasdaq, Company, Vero, Saint-Herblain, Chikungunya, 1018, Marketing, World Health Organization, Pharmaceutical industry, Kingdom, VLA2001, Valneva SE

Saint-Herblain (France), September 6, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that The Lancet Infectious Diseases (The Lancet ID), a peer-reviewed medical journal, has published the Companys pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.

Key Points: 
  • Saint-Herblain (France), September 6, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that The Lancet Infectious Diseases (The Lancet ID), a peer-reviewed medical journal, has published the Companys pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.
  • Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, This Lancet publication is a strong scientific and developmental validation of the work that has been accomplished at Valneva.
  • The Company published safety and immunogenicity data from the Phase 1/2 trial of VLA2001 in the Journal of Infection3 in June 2022.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001

Retrieved on: 
Monday, August 29, 2022
AstraZeneca, COVID-19, EMA, BMI, EU, Technology, Safety, Vaccination, Immunity, WHO, Vaccine, VLA, Seroconversion, 3-fold, Infection, Hope, Lyme disease, Asthma, Euronext Paris, Severe acute respiratory syndrome coronavirus 2, MD, GMT, CpG, Nasdaq, Company, Vero, Saint-Herblain, Chikungunya, World, Marketing, RNA transfection, 1018, T cell, World Health Organization, Pharmaceutical industry, Kingdom, VLA2001

Saint-Herblain (France), August 29, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001.

Key Points: 
  • Saint-Herblain (France), August 29, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001.
  • Additional readouts from the Companys pivotal VLA2001-301 Cov-Compare trial showed persistent immunogenicity and first positive heterologous booster results following primary vaccination with ChAdOx1-S (AstraZeneca).
  • The safety profile of VLA2001 continues to be favorable and the vaccine was well tolerated up to Day 208.
  • This complements the positive homologous booster data weve generated in our Phase 1/2 and this Phase 3.

Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine

Retrieved on: 
Tuesday, August 23, 2022
AstraZeneca, COVID-19, EMA, Public health, EU, Technology, Vaccination, WHO, Vaccine, VLA, Strategic Advisory Group of Experts, Infection, Lyme disease, Euronext Paris, Severe acute respiratory syndrome coronavirus 2, MD, CpG, Nasdaq, Company, Vero, Saint-Herblain, Chikungunya, World, VLA2001, 1018, SAGE, Review, World Health Organization, Pharmaceutical industry, Kingdom, Immunization, Valneva SE

Saint-Herblain (France), August 23, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, confirms today that the World Health Organization (WHO) has issued recommendations for use of the Companys inactivated COVID-19 vaccine.

Key Points: 
  • Saint-Herblain (France), August 23, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, confirms today that the World Health Organization (WHO) has issued recommendations for use of the Companys inactivated COVID-19 vaccine.
  • WHO may further update its interim recommendations to include additional uses of Valnevas COVID-19 vaccine as new data are made available.
  • Valneva currently has agreements to supply VLA2001 to certain EU Member States2 and the Kingdom of Bahrain3.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate

Retrieved on: 
Thursday, August 18, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nausea, Biologics license application, Ageing, Public health, LMIC, Mortality, Genome, Trial of the century, Population, European Medicines Agency, Saint-Herblain, CHIKV, Priority, Rash, Lyme disease, European, Fever, CEPI, Euronext Paris, Marketing, COVID-19, Company, Infection, Program, VLA, Vaccine, Fast track (FDA), Disease, Aedes, Headache, Low, BLA, Nasdaq, Human, MD, Food, File, EMA, Alphavirus, Person, Pharmaceutical industry, Chikungunya

Chikungunya is a major public health threat that continues to grow, and no vaccine or specific treatments are currently available for this debilitating disease.

Key Points: 
  • Chikungunya is a major public health threat that continues to grow, and no vaccine or specific treatments are currently available for this debilitating disease.
  • This rolling BLA submission is part of the accelerated approval pathway agreed upon with the FDA in 20204.
  • Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes.
  • VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 120 countries.

Valneva Establishes an At-the-Market (ATM) Program on Nasdaq

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, Telephone, Risk, Form, SEC, Clinical trial, Research, Annual report, Central bank, Securities Act of 1933, Registration statement, Program, Madison Avenue, Jefferies Group, ADSS, Sale, Cosmetics, Patent, ATM, AMF, Euronext Paris, Annual general meeting, Chikungunya, European Central Bank, Polaris Sales Agreement, Commercial code, Jefferies, Prospectus, EDGAR, COVID-19, European Parliament, Vaccine, VLA, Time, The Annual Report, ADS, Code, Mass meeting, Saint-Herblain, Achievement, Lyme disease, European, Company, Infection, Register, Intention, Council, Security (finance), Bank, EU, Euronext, Nasdaq, Valneva SE

Only eligible investors (as described in greater detail below) may purchase ADSs under the ATM Program.

Key Points: 
  • Only eligible investors (as described in greater detail below) may purchase ADSs under the ATM Program.
  • The new ordinary shares will be admitted to trading on the regulated market of Euronext in Paris and the issued ADSs will trade on the Nasdaq Global Select Market (Nasdaq).
  • No offers or sales of ADSs under the ATM Program can be made until the Registration Statement is declared effective by the SEC.
  • This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the proposed ATM Program and the expected use of proceeds, if any, from the ATM Program.